MedTrace Logo

Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions

NCT04071756 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2024-02-07

Study results available
· View outcomes & findings →

Summary

This research is studying the preventative use of topical 0.1% tazarotene gel daily in addition to best practice standards to reduce the development of hand-foot skin reaction (HFSR).

Conditions

Interventions

DRUG

Topical Tazarotene

This medicine works by making the skin less inflamed and reducing the thickness and pain from lesions of the skin

OTHER

Placebo

A substance that has no therapeutic effect, used as a control in testing new drugs

Sponsors & Collaborators

Principal Investigators

  • Nicole LeBoeuf, MD · Dana-Farber Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-30
Primary Completion
2021-06-12
Completion
2022-07-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04071756 on ClinicalTrials.gov